| Literature DB >> 29622757 |
Yanhong Li1, Hui Liu1, Yubin Dong1.
Abstract
By performing a basic case-control study among a Chinese population, the aims of this study were to explore if single nucleotide polymorphisms (SNPs) within neurexin and neuroligin were associated with susceptibility to Hirschsprung's disease (HD). Eleven SNPs within neurexin and neuroligin were selected in this basic case-control study, and this study recruited 210 children with HD and 187 healthy children. The t-test and Χ2 test were used to find the difference between case and control in their clinical variables. OR and 95% CI were used to assess the association between HD susceptibility and neurexin/neuroligin polymorphisms/haplotypes. Several SNPs were significantly associated with altered risk of HD in the Chinese Han population, including rs1421589 within NRXN1, rs11795613 and rs4844285 within NLGN3, as well as rs5961397, rs7157669 and rs724373 within NLGX4X (all P<0.05). Further studies presented that the effects of rs1421589 within NRXN1, rs4844285 and rs11795613 within NLGN3, as well as rs5961397 within NLGX4X on HD phenotypes were also statistically significant (all P<0.05). Conclusively, the polymorphisms and haplotypes situated within neurexin and neuroligin were markedly associated with the onset of HD, implying that mutations of neurexin and neuroligin might serve as the treatment target for HD for the Chinese children. © American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.Entities:
Keywords: abdomen; polymorphism, genetic
Mesh:
Substances:
Year: 2018 PMID: 29622757 PMCID: PMC5992363 DOI: 10.1136/jim-2017-000623
Source DB: PubMed Journal: J Investig Med ISSN: 1081-5589 Impact factor: 2.895
Baseline characteristics of the children with Hirschsprung’s disease (case group) and healthy children (control group)
| Clinical features | Case group | Control group | t-Test | P value |
| Number | 210 | 187 | – | – |
| Age (month) | 7.30±1.18 | 7.35±1.08 | 0.44 | 0.661 |
| Weight (kg) | 7.15±0.46 | 8.42±0.53 | 1.8 | 0.073 |
| Height (cm) | 61.78±2.04 | 70.53±1.96 | 1.24 | 0.216 |
| Pathological features | ||||
| Short segment type | 69 | – | – | – |
| Long segment type | 101 | – | – | – |
| Total type | 40 | – | – | – |
Figure 1The linkage disequilibrium of single nucleotide polymorphism within (A) NRXN1 (ie, rs1363032 (chromosome 2: 49993858) and rs1421589 (chromosome 2: 50063015)), (B) NRXN3 ([ie, rs11624704 (chromosome 14: 78319734), rs7157669 (chromosome 14: 78471334) and rs724373 (chromosome 14: 78476555)), (C) NLGN1 (ie rs13074723 (chromosome 3: 173804307) and rs1488547 (chromosome 3: 173807978)) and (D) NLGN3 (ie rs11795613 (chromosome X: 71147478) and rs4844285 (chromosome X: 71150394) and NLGX4X (ie rs6529901 (chromosome X: 5937979) and rs5961397 (chromosome X: 6004425)).
Correlation between SNPs within neurexin/neuroligin and susceptibility to HD
| Gene | Rs number | Allele change | Group | Allele | HWE | Allelic model | Dominant model | Recessive model | |||||||
| W | M | P value | OR | 95% CI | P value* | OR | 95% CI | P value* | OR | 95% CI | P value* | ||||
| NRXN1 | rs1363032 | T>C | Case | 297 | 123 | 0.91 | 1.03 | 0.76 to 1.41 | 0.876 | 1.01 | 0.68 to 1.50 | 1.000 | 1.14 | 0.56 to 2.31 | 0.858 |
| Control | 267 | 107 | |||||||||||||
| rs1421589 | T>C | Case | 318 | 102 | 0.10 |
|
|
|
|
|
|
|
|
| |
| Control | 243 | 131 | |||||||||||||
| NRXN3 | rs11624704 | A>C | Case | 349 | 71 | 0.05 | 1.23 | 0.84 to 1.81 | 0.328 | 1.17 | 0.75 to 1.83 | 0.568 | 1.7 | 0.66 to 4.35 | 0.359 |
| Control | 321 | 53 | |||||||||||||
| rs7157669 | C>A | Case | 82 | 338 | 0.59 |
|
|
| 1.46 | 0.65 to 3.31 | 0.411 |
|
|
| |
| Control | 97 | 277 | |||||||||||||
| rs724373 | T>C | Case | 60 | 360 | 0.91 |
|
|
|
|
|
|
|
|
| |
| Control | 115 | 259 | |||||||||||||
| NLGN1 | rs13074723 | G>A | Case | 197 | 223 | 0.96 | 1.04 | 0.79 to 1.37 | 0.831 | 1.06 | 0.66 to 1.71 | 0.811 | 1.04 | 0.67 to 1.62 | 0.911 |
| Control | 179 | 195 | |||||||||||||
| rs1488547 | A>G | Case | 179 | 241 | 0.72 | 1.26 | 0.95 to 1.67 | 0.116 | 1.43 | 0.88 to 2.33 | 0.174 | 1.3 | 0.85 to 2.01 | 0.231 | |
| Control | 181 | 193 | |||||||||||||
| NLGN3 | rs11795613 | A>G | Case | 279 | 141 | 0.98 |
|
|
|
|
|
|
|
|
|
| Control | 162 | 212 | |||||||||||||
| rs4844285 | G>A | Case | 233 | 187 | 0.97 |
|
|
|
|
|
|
|
|
| |
| Control | 152 | 222 | |||||||||||||
| NLGX4X | rs6529901 | C>T | Case | 273 | 147 | 1.00 | 1.2 | 0.89 to 1.61 | 0.257 | 1.23 | 0.83 to 1.84 | 0.313 | 1.33 | 0.70 to 2.51 | 0.426 |
| Control | 258 | 116 | |||||||||||||
| rs5961397 | T>C | Case | 292 | 128 | 1.00 |
|
|
|
|
|
|
|
|
| |
| Control | 201 | 173 | |||||||||||||
*The P value has been adjusted.
The bold values indicated significant results. HD, Hirschsprung’s disease; HWE, Hardy-Weinberg equilibrium; M, mutant allele; SNP, single nucleotide polymorphism; W, wild allele.
Correlation between haplotypes within neurexin/neuroligin and susceptibility to HD
| Gene | Haplotype | Case (frequency) | Control (frequency) | χ2 | P value* | OR | 95% CI |
|
| CT | 123 (0.293) | 72 (0.193) | 10.75 | 0.001 |
|
|
| TC | 102 (0.243) | 96 (0.257) | 0.20 | 0.653 | 0.93 | 0.67 to 1.28 | |
| TT | 195 (0.464) | 171 (0.457) | 0.04 | 0.842 | 1.03 | 0.78 to 1.36 | |
|
| AAC | 267 (0.636) | 165 (0.441) | 21.26 | <0.001 |
|
|
| ACC | 22 (0.052) | 58 (0.156) | 26.51 | <0.001 |
|
| |
| ACT | 60 (0.143) | 26 (0.071) | 8.76 | 0.003 |
|
| |
| CAC | 71 (0.169) | 29 (0.079) | 12.17 | <0.001 |
|
| |
|
| AG | 223 (0.531) | 103 (0.276) | 53.01 | <0.001 |
|
|
| GA | 179 (0.426) | 89 (0.239) | 31.04 | <0.001 |
|
| |
| GG | 18 (0.043) | 90 (0.24) | 65.44 | <0.001 |
|
| |
|
| AACT | 46 (0.11) | 30 (0.08) | 1.35 | 0.245 | 1.33 | 0.82 to 2.16 |
| AATT | 0 (0) | 17 (0.046) | 19.58 | <0.001 |
|
| |
| AGCT | 86 (0.205) | 14 (0.037) | 47.18 | <0.001 |
|
| |
| AGTT | 147 (0.35) | 18 (0.049) | 102.81 | <0.001 |
|
| |
| GACC | 128 (0.305) | 41 (0.109) | 41.10 | <0.001 |
|
| |
| GACT | 13 (0.031) | 42 (0.112) | 21.95 | <0.001 |
|
|
*The P value has been adjusted.
The bold values indicated significant results. HD, Hirschsprung’s disease.
Correlation between SNPs within neurexin/neuroligin and HD phenotypes
| Gene | rs number | Allele change | Genotype | SS type | LS type | Total type | SS type versus LS type | SS type versus total type | ||
| χ2 | P value* | χ2 | P value* | |||||||
| NRXN1 | rs1363032 | T>C | TT | 40 | 47 | 19 | 1.12 | 0.291 | 2.83 | 0.093 |
| TC | 24 | 48 | 13 | |||||||
| CC | 5 | 6 | 8 | |||||||
| rs1421589 | T>C | TT | 36 | 65 | 20 | 2.35 | 0.126 | 0.04 | 0.846 | |
| TC | 28 | 31 | 17 | |||||||
| CC | 5 | 5 | 3 | |||||||
| NRXN3 | rs11624704 | A>C | AA | 46 | 78 | 28 | 2.42 | 0.12 | 0 | 0.964 |
| AC | 18 | 19 | 8 | |||||||
| CC | 5 | 4 | 4 | |||||||
| rs7157669 | C>A | CC | 4 | 4 | 3 | 0.03 | 0.859 | 2.39 | 0.122 | |
| CA | 17 | 27 | 16 | |||||||
| AA | 48 | 70 | 21 | |||||||
| rs724373 | T>C | TT | 3 | 2 | 3 |
|
|
|
| |
| TC | 5 | 30 | 9 | |||||||
| CC | 61 | 69 | 28 | |||||||
| NLGN1 | rs13074723 | G>A | GG | 12 | 26 | 8 | 1 | 0.318 | 2.57 | 0.109 |
| GA | 47 | 41 | 17 | |||||||
| AA | 10 | 34 | 15 | |||||||
| rs1488547 | A>G | AA | 13 | 19 | 6 | 2.67 | 0.102 | 0.91 | 0.341 | |
| AG | 25 | 55 | 23 | |||||||
| GG | 31 | 27 | 11 | |||||||
| NLGN3 | rs11795613 | A>G | AA | 22 | 46 | 26 |
|
|
|
|
| AG | 32 | 50 | 9 | |||||||
| GG | 15 | 5 | 5 | |||||||
| rs4844285 | G>A | GG | 16 | 29 | 20 | 0.69 | 0.407 |
|
| |
| GA | 37 | 52 | 14 | |||||||
| AA | 16 | 20 | 6 | |||||||
| NLGX4X | rs6529901 | C>T | CC | 37 | 38 | 14 | 1.93 | 0.165 | 3.62 | 0.057 |
| CT | 24 | 53 | 18 | |||||||
| TT | 8 | 10 | 8 | |||||||
| rs5961397 | T>C | TT | 23 | 56 | 23 |
|
| 2 | 0.158 | |
| TC | 37 | 41 | 10 | |||||||
| CC | 9 | 4 | 7 | |||||||
*The P value has been adjusted.
The bold values indicated significant results. HD, Hirschsprung’s disease; LS, long segment; SNP, single nucleotide polymorphism; SS, short segment.
Figure 2The mechanism underlying the effects of neurexin and neuroligin on synapse-related information transfer. As an action potential is initiated (①), the Ca2+-channel of the presynaptic terminal would be open (②), which triggers inflowing of Ca2+. Subsequently, the synaptic vesicles within the presynaptic cell would be fused with the presynaptic plasma membrane (③), and neurotransmitters are released from vesicles into the synaptic cleft (④). Ultimately, the neurotransmitters would contact with the postsynaptic receptors, through which the process of information transfer is accomplished (⑤).